Agilent Technologies, Inc.

DB:AG8 Stock Report

Market Cap: €34.7b

Agilent Technologies Valuation

Is AG8 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AG8 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: AG8 (€120.2) is trading below our estimate of fair value (€129.96)

Significantly Below Fair Value: AG8 is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AG8?

Key metric: As AG8 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for AG8. This is calculated by dividing AG8's market cap by their current earnings.
What is AG8's PE Ratio?
PE Ratio25.8x
EarningsUS$1.41b
Market CapUS$36.51b

Price to Earnings Ratio vs Peers

How does AG8's PE Ratio compare to its peers?

The above table shows the PE ratio for AG8 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average64.4x
SRT3 Sartorius
187.6x36.4%€13.1b
1SXP SCHOTT Pharma KGaA
25.7x15.9%€3.9b
GXI Gerresheimer
21.7x21.7%€2.5b
MRK Merck KGaA
22.6x10.7%€60.9b
AG8 Agilent Technologies
25.8x4.1%€36.5b

Price-To-Earnings vs Peers: AG8 is good value based on its Price-To-Earnings Ratio (25.8x) compared to the peer average (64.4x).

Price to Earnings Ratio vs Industry

How does AG8's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
AG8 25.8xIndustry Avg. 36.9xNo. of Companies4PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: AG8 is good value based on its Price-To-Earnings Ratio (25.8x) compared to the European Life Sciences industry average (37.1x).

Price to Earnings Ratio vs Fair Ratio

What is AG8's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AG8 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio25.8x
Fair PE Ratio18.8x

Price-To-Earnings vs Fair Ratio: AG8 is expensive based on its Price-To-Earnings Ratio (25.8x) compared to the estimated Fair Price-To-Earnings Ratio (18.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst AG8 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€120.20
€142.59
+18.6%
5.5%€156.73€128.24n/a17
Nov ’25€119.26
€138.65
+16.3%
5.5%€152.39€124.69n/a17
Oct ’25€132.80
€133.79
+0.7%
6.6%€149.06€117.44n/a17
Sep ’25€128.34
€131.89
+2.8%
7.0%€147.53€116.23n/a17
Aug ’25€130.26
€129.73
-0.4%
6.6%€142.26€114.73n/a16
Jul ’25€118.48
€130.67
+10.3%
6.9%€144.83€116.80n/a16
Jun ’25€120.94
€130.31
+7.7%
7.2%€143.13€115.43n/a17
May ’25€129.80
€141.20
+8.8%
6.2%€154.18€121.47n/a18
Apr ’25€135.75
€135.46
-0.2%
7.5%€151.98€115.14n/a18
Mar ’25€126.80
€133.64
+5.4%
7.7%€152.26€115.35n/a17
Feb ’25€120.15
€128.88
+7.3%
8.1%€152.34€110.80n/a17
Jan ’25€125.65
€123.29
-1.9%
11.1%€150.32€91.10n/a18
Dec ’24€116.80
€122.03
+4.5%
10.2%€138.69€91.85n/a17
Nov ’24€95.86
€129.06
+34.6%
11.4%€152.86€98.47€119.2617
Oct ’24€107.05
€132.25
+23.5%
10.3%€154.33€99.41€132.8017
Sep ’24€111.35
€130.48
+17.2%
9.3%€150.24€101.39€128.3417
Aug ’24€110.20
€130.22
+18.2%
9.1%€148.23€104.58€130.2617
Jul ’24€107.90
€132.71
+23.0%
7.6%€149.47€115.54€118.4817
Jun ’24€107.85
€137.82
+27.8%
7.9%€159.07€117.90€120.9417
May ’24€120.40
€147.86
+22.8%
7.3%€158.81€115.91€129.8017
Apr ’24€123.44
€152.99
+23.9%
7.0%€163.19€119.11€135.7516
Mar ’24€128.96
€152.99
+18.6%
7.0%€163.19€119.11€126.8016
Feb ’24€138.58
€150.57
+8.7%
6.8%€157.52€117.68€120.1516
Jan ’24€140.82
€150.98
+7.2%
6.9%€160.11€119.61€125.6516
Dec ’23€147.92
€151.23
+2.2%
6.9%€161.50€120.65€116.8016
Nov ’23€139.90
€149.35
+6.8%
8.6%€170.12€115.08€95.8616

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Regeneron Pharmaceuticals

US$81.4b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

RGO

US$713.60

7D

-8.3%

1Y

-2.5%

Amneal Pharmaceuticals

US$2.6b

Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.

2DT

US$7.60

7D

-2.6%

1Y

86.3%

Almirall

€1.8b

A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.

E2Z

€8.35

7D

-4.5%

1Y

-2.3%